Halo Pharma to become a stand-alone Drug Product Contract Development and Manufacturing Organization (CDMO)

Whippany, NJ – January 27, 2026 SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to

Halo Pharma Enhances Manufacturing Capabilities with Macro-Pactor Investment

Whippany, NJ – December 16, 2025 New addition enhances manufacturing continuity and supports seamless progression from early-phase development to late-stage production Macro-Pactor® to be online

Halo Pharma Names Laurent Malgouyres Site Director for Mirabel, Canada Facility

Whippany, NJ – October 14, 2025 Malgouyres joins Halo with over 14 years of operational experience in the pharmaceutical industry As site director, he will

John Bender Joins Woodstock Sterile Solutions, Halo Pharma as VP, Business Development

Woodstock, IL, August 12, 2025  Bender brings 35 years of pharmaceutical industry experience to dual role Woodstock Sterile Solutions, a leading blow-fill-seal (BFS) contract development

The Noramco Group Invests $25 Million in Halo Pharma’s Whippany Facility to Offer Sterile Injectable Manufacturing

WILMINGTON, Del. and WHIPPANY, New High-Speed Filling Line to Support Growing Demand for Sterile Injectables and Strengthen Domestic Supply Chain Learn More About Halo Pharma’s